Table 1.
Study baseline characteristics of HIV‐infected adolescents (N = 327)
| Variable | n (%)/ Median (IQR) |
|---|---|
| Sex | |
| Male | 170 (52) |
| Female | 157 (48) |
| Mode of HIV acquisition | |
| Perinatal | 314 (96) |
| Non‐perinatal | 9 (2.8) |
| Unknown | 4 (1.2) |
| Age (years) | |
| Study entry | 10.6 (10.0 to 12.8) |
| Diagnosis | 5.2 (1.3 to 9.1) |
| ART initiation | 7.2 (3.2 to 9.9) |
| Study follow‐up time (years) | 4.9 (3.6 to 6.6) |
| Duration of ART at entry (years) | 4.4 (1.8 to 7.6) |
| ART naïve at entry | 33 (10) |
| ART Regimen at entry | 327 (100) |
| NNRTI | 201 (61.5) |
| Protease Inhibitor | 124 (37.9) |
| Holding | 2 (0.6) |
| CD4 at entry (cells/μL) | 710 (486 to 945) |
ART, antiretroviral therapy; Holding, non‐ suppressive single drug regimen consisting of lamivudine; NNRTI, non‐nucleoside Reverse Transcriptase Inhibitor.